Long term levels of bile acids, fibroblast growth factor-19, and glucagon-like peptide-1 after bariatric surgery

Objectives: Glucagon-like peptide-1(GLP-1) is a hormone often measured in the short-term following Roux-en-Y gastric bypass (RYGB) due to its elevation and association with improvement of glucose metabolism. We examined the durability of this effect in patients with type 2 diabetes mellitus (DM) in...

Full description

Bibliographic Details
Published in:	Asian Journal of Surgery
Main Authors:	Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Subjects:	GLP-1 Bile acids FGF-19 Long-term Bariatric surgery
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958424023133

Similar Items

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01)

The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis
by: Asma Mousavi, et al.
Published: (2025-08-01)

Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action
by: Jun Zhang, et al.
Published: (2017-02-01)

Bile acid signalling and its role in anxiety disorders
by: Simin Chen, et al.
Published: (2023-11-01)

Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01)

Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism
by: Fengyuan Tian, et al.
Published: (2022-11-01)

Gut Microbiota Metabolism of Bile Acids Could Contribute to the Bariatric Surgery Improvements in Extreme Obesity
by: Luis Ocaña-Wilhelmi, et al.
Published: (2021-10-01)

Diagnostic Value of Bile Acids and Fibroblast Growth Factor 21 in Women with Polycystic Ovary Syndrome
by: Jennie L. Yoost, et al.
Published: (2022-09-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity
by: Jennifer Wilbrink, et al.
Published: (2024-12-01)

Radiation-induced oxidative injury of the ileum and colon is alleviated by glucagon-like peptide-1 and -2
by: Mustafa Deniz, et al.
Published: (2015-04-01)

Significance of intestinal microbiota in implementing metabolic effects of bariatric surgery
by: Marina A. Berkovskaya, et al.
Published: (2021-03-01)

Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway
by: Ziyang Zhou, et al.
Published: (2025-04-01)

L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis
by: Sarah E. Martchenko, et al.
Published: (2021-12-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

Physiological Role of Bile Acids Modified by the Gut Microbiome
by: Yoshimitsu Kiriyama, et al.
Published: (2021-12-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
by: Tyler S. Oesterle, et al.
Published: (2025-06-01)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
by: Syed Faizan Mehdi, et al.
Published: (2023-05-01)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
by: Isabella Zaffina, et al.
Published: (2023-02-01)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024-08-01)

Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases
by: Sihui Deng, et al.
Published: (2025-10-01)

Glucagon-like peptide-1 receptor agonists in neoplastic diseases
by: Lisan Ji, et al.
Published: (2024-09-01)

Gallstone Formation Follows a Different Trajectory in Bariatric Patients Compared to Nonbariatric Patients
by: Sylke Haal, et al.
Published: (2021-10-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Equine glucagon-like peptide-1 receptor physiology
by: Murad H. Kheder, et al.
Published: (2018-01-01)

Intestine-derived fibroblast growth factor 19 alleviates lipopolysaccharide-induced liver injury by regulating bile acid homeostasis and directly improving oxidative stress
by: Xiaomeng Tang, et al.
Published: (2025-01-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Glucagon-like Peptide-1 Levels and Related Parameters in Rheumatoid Arthritis Patients Prone to Atherosclerosis
by: Noorhan K. Shafeeq, et al.
Published: (2017-06-01)

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury
by: Ali Ismaeil, et al.
Published: (2022-06-01)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Suppressed intestinal secondary bile acids in moxifloxacin-induced hyperglycemia: studies in normal and diabetic GK rats
by: Yewen Sun, et al.
Published: (2025-04-01)

Opioid-like peptides and ghrelin mitigation of bariatric results depends on obesity level
by: Michał Dyaczyński, et al.
Published: (2020-02-01)

The mood stabilizers lithium and valproate disrupt hepatic and intestinal farnesoid X receptor signalling and increase bile synthesis in the rat
by: Sofia Cussotto, et al.
Published: (2025-09-01)

Serum Ghrelin and Glucagon-like Peptide 1 Levels in Children with Prader-Willi and Bardet-Biedl Syndromes
by: Doğa Türkkahraman, et al.
Published: (2024-06-01)

Neural regulation of hindlimb muscle contraction-induced glucagon-like peptide-1 and peptide YY secretion in rats
by: Shin-ya Ueda, et al.
Published: (2015-03-01)

Bile acids, gut microbiota and metabolic surgery
by: Jui Tu, et al.
Published: (2022-08-01)

Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy following bariatric surgery
by: Emma C Donigan, et al.
Published: (2025-09-01)